Skip To The Main Content
2023 Micro

2023 PDA Pharmaceutical Microbiology Conference

Oct 02 - Oct 04, 2023
Washington, DC

Macro Impacts from the Micro-Universe

  • Conference
  • The Americas

left to save

Program Highlights

We are accepting additional submissions for poster presentations! Abstracts are due 30 June.



The 2023 PDA Pharmaceutical Microbiology Conference continues the ongoing tradition of addressing the opportunities and challenges, most relevant, to the future of microbiology in today’s global market. Join new and seasoned professionals from all facets of the field, including global industry, academia, and regulatory authorities, to share insights on how to best prepare for the future through the sharing of best practices, development of standards, and integration of innovative technologies.


  • Kurt Jacques, GSK (Co-Chair)
  • Vineeta PradhanU.S. FDA (Co-Chair)
  • Frederic Ayers, Eli Lilly and Company
  • Daniel Bice, Teva
  • Yeissa Chabrier-Rosello, U.S. FDA
  • Lori Daane, bioMérieux, Inc.
  • Lynne Ensor, Parexel
  • Mitch Garber, 2seventybio
  • Marc Glogovsky, ValSource, Inc.
  • Simleen Kaur, U.S. FDA
  • Heike Merget-Millitzer, Janssen Pharmaceutical Companies of Johnson & Johnson – J&J
  • Dawn Watson, Merck & Co., Inc.
  • Jason Willett, Veltek Associates


  • Day 1
  • Day 2
  • Day 3

    14:30 – 19:00 | Registration Open


    07:00 – 17:30 | Registration Open

    07:30 – 08:30 | Continental Breakfast

    08:30 – 10:00 | P1: A Cancer Journey as Seen through the Patient Lens 
    Moderator: Mitch B. Garber, RPh, Head of Quality Services & Compliance, 2seventy bio

    Rob Weker worked his entire career in healthcare and is a three-time cancer survivor, including pancreatic cancer. He will share his journey from diagnosis through the different treatment options of his pancreatic cancer. Rob will provide a special perspective from the patient’s lens on how he and his family made many difficult treatment decisions while having continuous challenges from his medical insurance company. Rob will share his thoughts on going against his family and several doctor’s advice and entered a clinical trial study which he believes ultimately saved his life. Everyone has been touched somehow by cancer either directly or indirectly which drives Rob’s passion to share his learnings and journey with everyone he can. He also hopes his message will influence and motivate the scientists and regulatory professionals at the PDA event.

    08:30 | Welcome Remarks

    08:40 | Rob Weker, MBA, Principal, Weker Advisors

    09:20 | Q&A

    10:00 – 10:45 | Networking Break

    10:45 – 12:15  | Concurrent Sessions

    A1: Optimizations in Decontamination and Sterilization
    Moderator: Dawn Watson, Director, Micro Quality & Sterility Assurance, Merck & Co., Inc.

    Aside from HEPA filters, no other advancement in the aseptic processing industry has more effectively addressed the issue of environmental contamination of critical zone processes than isolators. For such an impactful technology with decades of history, implementation of isolators has been regrettably slow. One of the major obstacles to isolator technology is validation of the Vapor Phase Hydrogen Peroxide (VPHP) decontamination cycle. This session will provide insights into recommended best practices for VPHP cycle development from an industry collaboration, an introduction to enzyme indicators and optimization of validation approaches that deliver effective and more efficient decontamination cycles.  

    While the use of isolators limits the risk of contamination, aseptic processing areas are still in use today. It is imperative to maintain strict control of these environments, which is in part accomplished through a robust cleaning and disinfection program that utilizes sterilized or pre-sterile disinfection agents. This session will also provide the essential elements of sterility validation for gamma-irradiated disinfection agents and how to reduce the risk of contamination while considering their chemical stability once opened.  

    10:45 | Optimizing Decontamination Cycles for Aseptic Processing Isolators
    Joseph E. McCall, SM (NRCM), Director, QA Technical Services, ADMA Biologics

    11:05 | BioPhorum Isolator Good Operating Practices Team: Industry Guidance for Vapor Phase Hydrogen Peroxide Cycle Development
    Terrence Hollis, Senior Manager, Global Technology and Engineering, Pfizer Inc.

    11:25 | Sterility, Sterilants, and Sterilization
    Kenneth M. Wiencek, BS, MS, PhD, Principal Microbiologist, Contec, Inc.

    11:55 | Q&A

    B1: Elements of Effective and Robust Microbiology Laboratory Investigations
    Moderator: Heike Merget-Millitzer, PhD, Microbiology CoE Lead, Janssen Pharmaceutical Companies of Johnson & Johnson – J&J

    Inadequate performance and documentation of investigations represent a large proportion of observations from health authorities. In this session, the presenters will discuss best practices and examples for conducting effective and robust Microbiology Laboratory Investigations in support of a thorough root cause analysis. Elements to consider for aseptic process simulation or sterility test failures as well as for environmental monitoring limit excursions will be addressed. The importance of identifying the type of contaminant to determine the root cause and to define respective remediation measures will also be highlighted.

    10:45 | Points to Consider for Complex Microbiological Investigations Involving the Aseptic Process
    Angie L. Bragdon, Senior Principal Scientist, Eli Lilly and Company

    11:05 | Get Out from Behind your Computer to Conduct Comprehensive EM Investigations
    Jaime Kaho’ohanohano, BS, Senior Microbiology Consultant, Microrite Inc.

    11:35 | Investigating Cleanroom Contamination and Disinfection Strategies
    Dan A. Klein, Sr. Technical Service Manager, STERIS Corporation

    11:55 | Q&A

    C1: Endotoxins and Pyrogens: Next Generation Testing Platforms
    Moderator: Simleen Kaur, MSc, Biologist, Team Lead, OCBQ, CBER, U.S. FDA

    It is time to remove barriers and adopt innovative platforms for detection of Endotoxins and Pyrogens during production and testing of pharmaceutical products. The proven efficacy of the modern methods provides an opportunity for the pharmaceutical industry to modernize traditional procedures and contribute significantly to the conservation of animals. This session will focus on evaluation of Recombinant Factor C and Monocyte Activation Test for safety testing during manufacturing and release of products.

    10:45 | Characterization of Endotoxin Detecting Recombinant Factor C Products for Evaluation of Manufacturing Quality and Assay Performance
    Talia Faison, MS, CQA, Biologist, CDER, U.S. FDA

    11:05 | Suitability of rFC-Based Endotoxin Tests: A Comparison Study Including Different Pharmaceutically Relevant Grades of Water
    Andre Kriegeskorte, PhD, Global Expert Microbiology, GSK

    11:25 | Monocyte Activation Test: A Case Study from Method Development and Validation to Release Testing of Drug Products
    Maria Gajewi, Manager Endotoxin Services, Microcoat Biotechnologie GmbH
    Jonas van den Berg, Global Quality Manager, Roche Diagnostics GmbH

    11:55 | Q&A

    12:15 – 13:45 | Grand Opening of the Exhibit Hall and Networking Lunch

    13:45 – 15:15 | Concurrent Sessions

    A2: Reflecting on “Microbiology Testing of the Future”
    Moderator: Kurt Jaecques, MA, Global Aseptic Technologies Lead Monitoring & Control, GSK

    Reflecting on microbiology testing of the future, our first thoughts guide us towards implementation of Rapid Microbial Methods (RMM) to allow fast release of microbial QC testing results. Whilst this should indeed be one of the main goals, it is not the only one. Of equal importance is the immediate access to data in the right format. Finally, within this lab of the future, we will need competent microbiologists, able to follow this evolution and able to make the right decisions fast and effectively. Within this session, we will be covering these three aspects by looking at a RMM for mycoplasma, how we efficiently can access and trend our data, and finally how we can build and ensure the right competencies for our microbiology experts for the future.

    13:45 | Implementation of a Novel Mycoplasma Testing Technology which Facilitates the Evolution Towards Increased Automation and Real-Time-Release in Microbiology Labs          
    Heike Merget-Millitzer, PhD, Microbiology CoE Lead, Janssen Pharmaceutical Companies of Johnson & Johnson – J&J

    14:05 | A Novel Method to Extract Environmental Monitoring Data from Paper Records for Use in EM Monitoring and Trending    
    Jon R. Voss, MS, VP, Head of Quality, Abeona Therapeutics
    Liz Maida, BSE, President and Co-Founder Fathom

    14:30 | Pharmaceutical Microbiologists: Training for Competency in the Next Decade and Beyond
    Donald C. Singer, MA, ASQ Fellow, CPGP, Senior Microbiology Technical Consultant, North America, Ecolab
    Radha Tirumalai, PhD, Director, Merck & Co., Inc.

    14:55 | Q&A

    Moderator: Yeissa M. Chabrier-Rosello, PhD, Senior Pharmaceutical Quality Assessor, OPQ, CDER, U.S. FDA

    13:45 | Sterile Compounding: Clarity from Chaos
    Abby A. Roth, CMQ/OE, Owner/Microbiologist, Pure Microbiology, LLC

    14:05 | Reyes Candau-Chacon, PhD, Quality Assessment Lead, OPQ, CDER, U.S. FDA

    14:25 | 
    U.S. FDA Representative Invited

    14:45 | Q&A

    C2: Endotoxin Masking
    Moderator: Moderator: Josh Eaton, MS, Director, Scientific and Regulatory Affairs, PDA

    13:45 | Overcoming Low Endotoxin Recovery: From Theory to Practice
    Jessica V. Hankins, PhD, Associate Scientific Director, Bristol Myers Squibb

    14:10 | The Impact of Endotoxin Masking on the Removal of Endotoxin during Manufacturing of a Biopharmaceutical Drug Product
    Jessica Stolzenberger, Associate Director Late Stage Downstream Development, Boehringer Ingelheim GmbH & Co. KG

    14:30 | Endotoxin Masking: Dependency on Container Type and Material
    Bernhard Illes, PhD, Project Leader Endotoxin Services, Microcoat Biotechnologie GmbH

    14:55 | Q&A

    15:15 – 16:00 | Networking Break in the Exhibit Hall

    16:00 – 17:00 | P2: Spillover
    Moderator: Frederic B. Ayers, Advisor - Sterility Assurance, Global Parenteral Products Network, Eli Lilly and Company

    Dr. David Kennedy is an Assistant Professor of Biology studying pathogen ecology at Penn State University.  Dr. Kennedy will be presenting an educational session on pathogen spillover into humans and the challenges associated with experimentally studying spillover in the lab. According to Dr Kennedy, pathogens spill over into humans frequently but understanding “the likelihood that a virus will be transmissible in a new host is hugely challenging, especially with the replication needed to gain scientific insight”. Dr. Kennedy will present his research model of using nematodes as a unique host organism and how this model has promise to predict future crossovers before they develop into global pandemics.

    16:00 | David Kennedy, Assistant Professor of Biology, University of Pennsylvania

    16:30 | Q&A

    17:00 – 18:00 | Networking Reception in the Exhibit Hall


    07:15 – 18:00 | Registration Open

    07:15 – 08:45 | Continental Breakfast

    08:30 – 10:00 | Microbiology/Environmental Monitoring Interest Group 
    IG Leaders: Kurt Jaecques, MA, Global Aseptic Technologies Lead Monitoring & Control, GSK and Marc Glogovsky, MS, SM (NRCM), Business Unit Manager/Senior Consultant – Microbiology, Valsource, Inc.

    08:45 – 10:00 | P3: Critical Thinking in a Regulated Environment
    Moderator: Vineeta A. Pradhan, PhD, Microbiologist, ONADE, CVM, U.S. FDA

    How does one establish a true risk-based approach for pharmaceutical manufacturing? This plenary session will focus on risk management and data governance. With the help of case studies, Peter Baker will explore factors that hinder implementation of regulatory expectations for both human and animal medical products. The speaker will present potential solutions to overcome inherent biases and experiences through critical thinking resources, as well as highlight simple tools to help meet the ultimate goal of knowledge management. Come join us for an exciting discussion that will benefit both regulators and industry members, alike!

    08:45 | Peter E. Baker, MS, President, Live Oak Quality Assurance

    09:15 | Q&A

    10:00 – 10:45 | Networking Break in the Exhibit Hall

    10:45 – 12:15  | Concurrent Sessions

    A3: Monitoring Efficiencies and Contamination Control Strategies
    Moderator: Daniel Bice, Associate Director Microbiologist Quality Compliance, Teva

    This session will encompass a quality risk management (QRM) tool to establish risk-based bioburden programs based on guidance principles in ICHQ11 and USP <1115> and their application to the facility and bioburden program. Additionally, how to create a robust global contamination control strategy and effectively implementing the aligned vision and the challenges with it to each site will be discussed.

    10:45 | Establish a Risk-Based Bioburden Control Program in a Low Bioburden API Production
    Peter Bisp, MA, QA Specialist, Novo Nordisk A/S  

    11:10 | Starting with the End in Mind: How to Implement a Multi-Site CDMO Contamination Control Strategy
    Marsha L. Steed, Head of Corporate Microbial Control and Viral Safety, Resilience

    11:35 | Q&A

    B3: Contamination Control in Annex 1: Two Case Studies
    Moderator: Kurt Jaecques, MA, Global Aseptic Technologies Lead Monitoring & Control, GSK

    The new EU Annex 1 clarified the expectations on multiple aspects and created a lot of debate on its correct implementation. The use of Quality Risk Management Principles (QRM) and more specifically, the requirement to generate a documented Contamination Control Strategy (CCS) triggered a lot of questions. How should one structure this document and how it could help drive continuous improvement of your processes? The revised Annex 1 re-activated some discussions as well on the rotation of disinfectants. In this session, we will be discussing a case study on the use of Risk Assessment and will evaluate surface EM data from different pharmaceutical organizations in order to evaluate what might be a suitable disinfectant rotation strategy.

    10:45 | Case Study on the Implementation of EU Annex 1 Risk Assessment Requirements
    Hilary A. Chan, MS, Principal Scientist, Takeda

    11:15 | Collaborating to Innovate Effective Disinfectant Rotation for Contamination Control
    Laura Brennan, Bsc, European Technical Consulting Leader, Ecolab
    Terra Kremer, BSc, Director of Microbiological Quality, Johnson & Johnson

    11:40 | Q&A

    12:15 – 13:45 | Networking Lunch in the Exhibit Hall

    13:45 – 15:15 | Concurrent Sessions

    A4: ATMPs: Translate Bench Development to Contamination-Controlled Manufacturing Process
    Moderator: Simleen Kaur, MSc, Biologist, Team Lead, OCBQ, CBER, U.S. FDA

    Advanced Therapeutic Medicinal Products (ATMPs), ‘next generation’ pharmaceuticals, offer novel technologies for new options for disease treatments based on cells, gene therapy, or tissue replacement. However, due to the diversity of product types and unique manufacturing processes, maintaining aseptic practices and monitoring quality of ATMPs have been a challenge. This session will focus on different approaches for developing microbial control strategies and establishing good aseptic practices for successful production of ATMPs under good manufacturing process.

    13:45 | Establishing a Microbial Contamination Testing Strategy for Live Biotherapeutic Products at Rise Therapeutics: Regulatory Requirements, Practical Experience, and Future Development Opportunities
    Joey Stair, Meng, Manager, Quality Assurance, Rise Therapeutics

    14:05 | The Power of High-Resolution Risk Data: Benefits of Data-Driven Manufacturing Control Guidelines for the Development of a Unified Contamination Control Strategy in Cell and Gene Therapy Manufacturing
    Sebastian Scheler, Managing Director, Innerspace GmbH

    14:30 | The Myth of the “Non-GMP” Space: The Criticality of Establishing Good Aseptic Practices in the Development Environment
    Amanda Curtis, Microbiology Consultant, ValSource, Inc.

    14:55 – 15:15 | Q&A

    B4: Cleanrooms
    Moderator: Frederic B. Ayers, Advisor - Sterility Assurance, Global Parenteral Products Network, Eli Lilly and Company

    13:45 | The Journey to Build a Clinical Cell and Gene Therapy Facility
    Mitch B. Garber, RPh, Head of Quality Services & Compliance, 2seventy bio

    14:10 | A Microbiologist’s Challenge to Find synergies between Product Testing and Environmental Monitoring: A Shared Journey when Qualifying New Manufacturing Areas for Multiple Modalities and Building a New Lab
    Mary Lynn Musco, Director, Merck & Co., Inc.
    Anita Casserly, Associate Director, Analytical R&D, MSD Ireland

    14:35 | Current Regulatory Inspection and Enforcement Trends for Aseptic Processing Operations
    Stephen E. Langille, PhD, Senior Microbiology Consultant, ValSource, Inc.

    15:00 | Q&A

    15:15 – 16:00 | Networking Break in the Exhibit Hall

    16:00 – 17:45 | Concurrent Sessions

    A5: Environmental Monitoring
    Moderator: Marc Glogovsky, MS, SM (NRCM), Business Unit Manager/Senior Consultant – Microbiology, Valsource, Inc.

    16:00 | What Really is Risk-Based Environmental Monitoring?
    Frederic B. Ayers, Advisor - Sterility Assurance, Global Parenteral Products Network, Eli Lilly and Company

    16:25 | Case Study: Application of Industry Harmonized Approach to Environmental Monitoring Performance Qualification
    Dawn Watson, Director, Micro Quality & Sterility Assurance, Merck & Co., Inc.
    Manshi M. Patel, Associate Director, Global Quality Assurance, Merck & Co., Inc.

    16:50 | Case Studies on Implementing a Global Risk-Based Environmental Monitoring Approach Across a Range of Production Facilities
    Jeremy Balster, Quality Control Microbiology Manager, Takeda

    17:15 | Q&A

    B5: Disinfection
    Moderator: Jason L. Willett, Midwest Manager, Veltek Associates, Inc.

    16:00 | Fundamentals of Disinfectant Efficacy Testing
    Crystal M. Booth, MM, ASQ-CQE, PMI-PMP, Sr. Technical Director, PSC Biotech

    16:25 | Case study: Effectiveness of Non-UV Anti-Microbial Light in Pharmaceutical Manufacturing Clean Room Gowning Area and Further Applications
    Victoria Raburn, Manager, Enviromental Compliance, Pfizer Inc.

    16:45 | Disinfectant Qualification: A Subjective Test            
    Ziva Abraham, PhD, CEO, Microrite, Inc

    17:15 | Q&A

    07:15 – 12:45 | Registration Open

    07:15 – 08:45 | Continental Breakfast

    07:30 – 08:15 | USP Microbiological Standards: An Overview and Update on Future Plans
    Moderator: Lynne Ensor A. Ensor, PhD, Senior Vice President & Head of Global Compliance Consulting, PAREXEL

    Practical and relevant standards firmly based in current scientific knowledge are critical to the continued assurance of the supply of quality drugs and devices. The United States Pharmacopeia (USP) is focused on providing such standards in its continuing work in key areas of importance including: endotoxins and pyrogens, rapid (modern) microbiological methods, bioburden contamination testing, microbial control, and sterility assurance. This session will provide an update on the current work plan of the USP General Chapters Microbiology Expert Committee and its related subcommittees. Included in this session will be an outline of the current priorities and future plans for the development of related standards, best practices for sterility assurance and microbial control, and stakeholder engagement opportunities.  Additionally, a brief refresher regarding the USP standard setting process, including opportunities for stakeholder engagement identified, will be discussed.

    07:30 | Mark G. Schweitzer, PhD, Principal, Mark Schweitzer Consulting LLC

    07:50 | Q&A

    08:30 – 10:00 | P4
    Moderator: Lori Daane, PhD, Sr Director of Scientific Affairs, bioMérieux, Inc.

    08:30 | Image Duplication, Manipulation, and Other Types of Problems in Biomedical Research
    Elisabeth M. Bik, PhD, Senior Consultant, Harbers Bik LLC

    09:15 | Q&A

    10:00 – 10:30 | Networking Break

    10:30 – 12:15 | P5: Ask the Regulators Panel Discussion
    Moderators: John W. Metcalfe, PhD, Master Microbiology Reviewer, OPQ, CDER, U.S. FDA and Vineeta A. Pradhan, PhD, Microbiologist, ONADE, CVM, U.S. FDA

    During this interactive session, U.S. FDA representatives will provide insight into questions posed by audience participants. The session is targeted to participants from all segments of the pharmaceutical industry for human and animal drugs and will provide valuable perspectives from agency experts who assess microbiological quality of non-sterile and sterile drugs and biologics. The panel members have extensive experience in several areas pertaining to product sterility assurance, including terminal sterilization, aseptic processing, and compounding. In addition, expert field investigators will provide their perspectives on inspection-related questions. Don’t miss this unique opportunity to interact with regulators in an open forum focused exclusively on your microbiology concerns!

    10:30 | Panel Discussion
    Renée S. Blosser, MS, Microbiologist, ONADE, CVM, U.S. FDA 
    Alonza E. Cruse
    , Director, Office of Pharmaceutical Quality Operations, OPQO, ORA, U.S. FDA 
    Tiffany M. Lucas, PhD, Gene Therapy CMC Product Reviewer, Biologist, OTAT, CBER, U.S. FDA 
    Additional U.S. FDA Representatives Invited

    12:00 | Closing Remarks

Highlighted Speakers

Ziva Abraham
Ziva Abraham
Microrite, Inc.
Frederic B. Ayers
Frederic B. Ayers
Eli Lilly and Company
Peter E. Baker
Peter E. Baker
Live Oak Quality Assurance
Elisabeth M.  Bik
Elisabeth M. Bik
Harbers Bik LLC
Mitch B. Garber
Mitch B. Garber
bluebird bio
Heike Merget-Millitzer
Heike Merget-Millitzer
Janssen Pharmaceutical Companies of Johnson & Johnson – J&J
Dawn M. Watson
Dawn M. Watson
Merck & Co., Inc.
Rob Weker
Rob Weker
Weker Advisors

Additional Information

  • Who Should Attend
    • Microbiology
    • Compliance
    • Engineering
    • Laboratory
    • Manufacturing
    • Product Development
    • QA/QC
    • Development
    • Regulatory Affairs
    • Research and Development
    • Validation
    Level of Expertise
    • Executives
    • Management
    • Scientist/Technicians
    Job Function
    • Scientist/Technicians
    • Research
    • Analyst
    • Bench Personnel
    • Pharmaceutical Industry Consultants
    • Regulatory Affairs
    • Health Authorities

Got a Question? We have answers

Contact Us


PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.

Grand Hyatt Washington

1000 H St NW
Washington, DC

Make a Reservation
Grand Hyatt Washington
  • Accommodations
    The Grand Hyatt Washington is the headquarter hotel for the 2023 PDA Pharmaceutical Microbiology Conference!

    Rate: $309 USD for single/double occupancy, plus state and local taxes
    Cut-Off Date: Friday, 01 September 2023 (after this date the discounted PDA rate is no longer guaranteed)
    Check-In: 16:00
    Check-Out: 11:00


    Phone: +1 (800) 233-1234, make sure to refer to group code G-PDA3 for the discounted conference rate
    Click on the reservation link above

    Individual Cancellation

    All cancellations must be received by 23:59 local time 48-hours before arrival to avoid a penalty of one night room and tax. Obtaining and canceling hotel reservations is the responsibility of the meeting participant. Individuals will be responsible for payment of their own cancellation fees.

  • Amenities
    The Grand Hyatt Washington is located in downtown Washington, DC, just blocks away from the National Mall. Immerse yourself in the historic sights, shopping, and alluring nightlife of the nation's capital. Whether you're visiting for business or pleasure, you'll enjoy exceptional comfort and service, as well as a direct connection to the city via the Metro Center station.

How to Get Here

By Air

The airports closest to the Grand Hyatt Washington hotel are Reagan National Airport (DCA, 3.6m/5.8km), Dulles International Airport (IAD, 25.3m/40.7km), and Baltimore-Washington International Airport (BWI, 31.5m/50.7km).

By Car

The Grand Hyatt Washington hotel is located at 1000 H Street NW, Washington, DC 20001. Both self-parking ($12-45+/day) and valet parking ($34-65+/day) are available.

Other Options

The metro stations closest to the Renaissance Washington, DC Downtown hotel are Metro Center (red/blue/orange/silver, connected to hotel), Gallery Place (red/yellow/green, 0.3m/0.5km), and Mount Vernon Square (yellow/green line, 0.6m/1km). Please visit for fare and schedule information.


Registration Fees

Early Registration
Registration Type By 06 August
Member $2,095
Non-Member $2,495
Gov./Health Authority/Academic (Member Only) $795
Student (Member Only) $495
Early Career Professional (Member Only) $1,295
Regular Registration
Registration Type After 06 August
Member $2,595
Non-Member $2,995
Gov./Health Authority/Academic (Member Only) $895
Student (Member Only) $595
Early Career Professional (Member Only) $1,395

Group Registration Discount: Register 3 people from the same organization as a group (at the same time) for the event and receive the 4th registration free. Other discounts cannot be applied.

GENERAL TERMS AND CONDITIONS: PDA will send you a confirmation letter within one week of payment being received. You must have this confirmation letter to be considered enrolled in a PDA event. If you have submitted a purchase order or requested an invoice, please be advised that a credit card guarantee is needed. PDA reserves the right to modify the material or speakers/trainers without notice or to cancel an event. If an event is cancelled, registrants will be notified by PDA immediately and will receive a credit (registration fee paid). PDA will not be responsible for any costs incurred by registrants due to cancellation. Please note that the attendee list is shared with attendees, trainers, and exhibitors and may be used to follow up on specific areas of interest after the event. Video, photo, and audio recordings are prohibited at all PDA events.

CANCELLATION: If a cancellation request is received 30 days before the event, a credit (registration fee paid minus a 200.00 USD/EUR processing fee) will be given. No credits will be given for cancellation requests received less than 30 days before the event. Cancellation requests must be emailed to [email protected].


Become a Sponsor

Interested in becoming a sponsor? Learn about opportunities and benefits.

Request Information

Featured Exhibitors

Attendee List Email Scam

Unfortunately, emails are circulating that offer to sell attendee lists for many of PDA’s conferences and events. These emails are sent by scammers.

Note: PDA does not sell its exhibitor or attendee lists, and no third-party is authorized to distribute or sell any lists related to our events. Statements claiming to offer our attendee lists are fraudulent. If you receive emails that propose to sell PDA conference attendee lists, do not engage with the sender and delete the message immediately.

Become an Exhibitor

Interested in becoming an exhibitor? Learn about opportunities and benefits.

Request Information

Media Partners

Related Events


Program Inquiries
  • Brooke Lustig, CMP
    Senior Manager, Programs
    Tel: +1 (301) 656-5900 ext. 111
Exhibition Inquiries
Training Course Inquiries

Tel: +1 (301) 656-5900
[email protected]

Tel: +49 (0) 30 43 655 08-10
[email protected]

Registration Customer Care

Tel: +1 (301) 656-5900 ext. 115
[email protected]

PDA Members Save Substantially